Lexicon Pharmaceuticals
LXRX
138 hedge funds and large institutions have $1.59B invested in Lexicon Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 49 increasing their positions, 39 reducing their positions, and 21 closing their positions.
41% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $9.32M
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
26% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 39
20% more capital invested
Capital invested by funds: $1.32B → $1.59B (+$268M)
5% more funds holding
Funds holding: 132 → 138 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$5.03M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.11M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.24M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.79M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$8.83M |
| 2 |
Millennium Management
New York
|
-$8.57M |
| 3 |
RA
Royce & Associates
New York
|
-$4.07M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.97M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.36M |
LXRX Hedge Fund Activity: Q2 2016 in Review
138 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2016, worth a combined $1.59B — up 20% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new LXRX positions and 21 closed out — a net gain of 7 holders — while 49 added to existing stakes and 39 trimmed.
The largest buyer was Norges Bank, adding an estimated $5.03M. The largest seller was UBS AM, cutting an estimated $8.83M.
- 138 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2016, up from 132 in Q1 2016.
- Funds reported $1.59B of Lexicon Pharmaceuticals stock for Q2 2016, up 20% quarter-over-quarter.
- 28 funds opened new Lexicon Pharmaceuticals positions in Q2 2016 and 21 closed out, a net change of +7 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2016 was Norges Bank, an estimated $5.03M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2016 was UBS AM, an estimated $8.83M sold.
Based on aggregated 13F filings for Q2 2016.